Clinical pharmacogenetics of irinotecan (CPT-11)

Drug Metabolism Reviews

Volumn 37, Issue 3, 2005, Pages 565-574

  Ando, Yuichi ^a   Hasegawa, Yoshinori ^b  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Irinotecan; Pharmacogenetics; Polymorphism; UDP glucuronosyltransferase

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; IRINOTECAN;

CANCER PATIENT; COLORECTAL CANCER; DIARRHEA; DNA POLYMORPHISM; DRUG MECHANISM; DRUG METABOLISM; GENE; GENETIC VARIABILITY; HUMAN; JAPAN; LEUKOPENIA; LUNG CANCER; NEUTROPENIA; PHARMACOGENETICS; PROMOTER REGION; REVIEW; UGT1A1 GENE;

CAMPTOTHECIN; HUMANS; PHARMACOGENETICS;

EID: 26444594410     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.1080/03602530500316254     Document Type: Review

References (48)

1. Akaba, K., Kimura, T., Sasaki, A., Tanabe, S., Ikegami, T., Hashimoto, M., Umeda, H., Yoshida, H., Umetsu, K., Chiba, H., Yuasa, I., Hayasaka, K. (1998). Neonatal hyperbilirubinemia and mutation of the bilirubin undine diphosphate-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese. Biochem. Mol. Biol. Int. 46:216.
2. Ando, Y., Figg, W. D. (2002). Irinotecan in small-cell lung cancer. N. Engl. J. Med. 346:1414-1415.
3. Ando, Y., Saka, H., Asai, G., Sugiura, S., Shimokata, K., Kamataki, T. (1998a). UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann. Oncol. 9:845-847.
4. Ando, Y., Chida, M., Nakayama, K., Saka, H., Kamataki, T. (1998b). The UGT1A1*28 allele is relatively rare in a Japanese population. Pharmacogenetics 8:357-360.
5. Ando, Y., Saka, H., Ando, M., Sawa, T., Muro, K., Ueoka, H., Yokoyama, A., Saitoh, S., Shimokata, K., Hasegawa, Y. (2000). Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60:6921-6926.
6. Ando, Y., Ueoka, H., Sugiyama, T., Ichiki, M., Shimokata, K., Hasegawa, Y. (2002a). Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan. Ther. Drug Monit. 24:111-116.
7. Ando, M., Ando, Y., Sekido, Y., Ando, M., Shimokata, K., Hasegawa, Y. (2002b). Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients. Jpn. J. Cancer Res. 93:591-597.
8. Beutler, E., Gelbart, T., Demina, A. (1998). Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc. Natl Acad. Sci. U. S. A. 95:8170-8174.
9. Bosma, P. J., Roy Chowdhury, J., Bakker, C., Gantla, S., de Boer, A., Oostra, B. A., Lindhout, D., Tytgat, G. N. J., Jansen, P. L. M., Oude Elferink, R. P. J., Roy Chowdhury, N. (1995). The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N. Engl. J. Med. 333:1171-1175.
10. Chabot, G. G., Abigerges, D., Catimel, G., Culine, S., de Forni, M., Extra, J. M., Mahjoubi, M., Hérait, P., Armand, J. P., Bugat, R., Clavel, M., Marty, M. E. (1995). Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann. Oncol. 6:141-151.
11. de Jonge, M. J. A., Verweij, J., de Bruijn, P., Brouwer, E., Mathijssen, R. H., van Alphen, R. J., de Boer-Dennert, M. M., Vernillet, L., Jacques, C., Sparreboom, A. (2000). Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin. J. Clin. Oncol. 18:195-203.
12. de Jong, F. A., Marsh, S., Mathijssen, R. H., King, C., Verweij, J., Sparreboom, A., McLeod, H. L. (2004). ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin. Cancer Res. 10:5889-5894.
13. Friedman, H. S., Petros, W. P., Friedman, A. H., Schaaf, L. J., Kerby, T., Lawyer, J., Parry, M., Houghton, P. J., Lovell, S., Rasheed, K., Cloughsey, T., Stewart, E. S., Colvin, O. M., Provenzale, J. M., McLendon, R. E., Bigner, D. D., Cokgor, L, Haglund, M., Rich, J., Ashley, D., Malczyn, J., Elfring, G. L., Miller, L. L. (1999). Irinotecan therapy in adults with recurrent or progressive malignant glioma. J. Clin. Oncol. 17:1516-1525.
14. Gagné, J. F., Montminy, V., Belanger, P., Journault, K., Gaucher, G., Guillemette, C. (2002). Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol. Pharmacol. 62:608-617.
15. Gong, Q. H., Cho, J. W., Huang, T., Potter, C., Gholami, N., Basu, N. K., Kubota, S., Carvalho, S., Pennington, M. W., Owens, I. S., Popescu, N. C. (2001). Thirteen UDP glucuronosyl-transferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics 11:357-368.
16. Hasegawa, Y., Sarashina, T., Ando, M., Kitagawa, C., Mori, A., Yoneyama, M., Ando, Y., Shimokata, K. (2004). Rapid detection of UGT1A1 gene polymorphisms by newly developed Invader assay. Clin. Chem. 50:1479-1480.
17. Innocenti, F., Undevia, S. D., Iyer, L., Chen, P. X., Das, S., Kocherginsky, M., Karrison, T., Janisch, L., Ramirez, J., Rudin, C. M., Yokes, E. E., Ratain, M. J. (2004). Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22:1382-1388.
18. Isselbacher, K. J. (1997). Bilirubin metabolism and hyperbilirubinemia. In: Fauci, A. S., Braunwald, E., Isselbacher, K. J., Wilson, J. D., Martin, J. B., Kasper, D. L., Hauser, S. L., Long, D. L., eds. Harrision's Principles of Internal Medicine 14th ed. New York: McGraw-Hill, 1672-1677.
19. Iyer, L., King, C. D., Whitington, P. F., Green, M. D., Roy, S. K., Tephly, T. R., Coffman, B. L., Ratain, M. J. (1998). Genetic predisposition to the metabolism of irinotecan (CPT-11): role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J. Clin. Invest. 101:847-854.
20. Iyer, L., Hall, D., Das, S., Mortell, M. A., Ramirez, J., Kim, S., Di Rienzo, A., Ratain, M. J. (1999). Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin. Pharmacol. Ther. 65:576-582.
21. Iyer, L., Das, S., Janisch, L., Wen, M., Ramirez, J., Karrison, T., Fleming, G. F., Yokes, E. E., Schilsky, R. L., Ratain, M. J. (2002). UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2:43-47.
22. Japan Society for Cancer Therapy (1993). Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. J. Jpn. Soc. Cancer Ther. 28:101-130.
23. Kitagawa, C., Ando, M., Ando, Y., Sekido, Y., Usui, M., Takahashi, K., Shimokata, K., Hasegawa, Y. (2004). Genetic polymorphisms of the multidrug resistance-associated protein 2 gene (ABCC2) and irinotecan toxicity. J. Clin. Oncol. 22:129. (suppl.; abstr. 2009).
24. Kitagawa, C., Ando, M., Ando, Y., Sekido, Y., Wakai, K., Imaizumi, K., Shimokata, K., Hasegawa, Y. (2005). Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1Al gene and irinotecan toxicity. Pharmacogenetics (in press).
25. Kubota, K., Nishiwaki, Y., Ohashi, Y., Saijo, N., Ohe, Y., Tamura, T., Negoro, S., Ariyoshi, Y., Nakagawa, K., Fukuoka, M. (2004). The Four-Arm Cooperative Study (FACS) for advanced non-small-cell lung cancer (NSCLC). J. Clin. Oncol. 22:618. (suppl.; abstr. 7006).
26. Mackenzie, P. I., Owens, I. S., Burchell, B., Bock, K. W., Bairoch, A., Bélanger, A., Fournel-Gigleux, S., Green, M., Hum, D. W., Iyanagi, T., Lancet, D., Louisot, P., Magdalou, J., Roy Chowdhury, J., Ritter, J. K., Schachter, H., Tephly, T. R., Tipton, K. E., Nebert, D. W. (1997). The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 7:255-269.
27. Marcuello, E., Altés, A., Menoyo, A., del Rio, E., Gómez-Pardo, M., Baiget, M. (2004). UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br. J. Cancer 91:678-682.
28. Mathijssen, R. H. J., van Alphen, R. J., Verweij, J., Loos, W. J., Nooter, K., Stoter, G., Sparreboom, A. (2001). Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res. 7:2182-2194.
29. Mathijssen, R. H., Verweij, J., de Bruijn, P., Loos, W. J., Sparreboom, A. (2002). Effects of St. John's wort on irinotecan metabolism. J. Natl. Cancer Inst. 94:1247-1249.
30. Mathijssen, R. H., Marsh, S., Karlsson, M. O., Xie, R., Baker, S. D., Verweij, J., Sparreboom, A., McLeod, H. L. (2003). Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin. Cancer Res. 9:3246-3253.
31. Mathijssen, R. H., de Jong, F. A., van Schaik, R. H., Lepper, E. R., Friberg, L. E., Rietveld, T., de Bruijn, P., Graveland, W. J., Figg, W. D., Verweij, J., Sparreboom, A. (2004). Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J. Natl. Cancer Inst. 96:1585-1592.
32. Meyerhardt, J. A., Kwok, A., Ratain, M. J., McGovren, J. P., Fuchs, C. S. (2004). Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer. J. Clin. Oncol. 22:1439-1446.
33. Monaghan, G., Ryan, M., Seddon, R., Hume, R., Burchell, B. (1996). Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 347:578-581.
34. Negoro, S., Fukuoka, M., Masuda, N., Takada, M., Kusunoki, Y., Matsui, K., Takifuji, N., Kudoh, S., Niitani, H, Taguchi, T. (1991). Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 83:1164-1168.
35. Ohe, Y., Sasaki, Y., Shinkai, T., Eguchi, K., Tamura, T., Kojima, A., Kunikane, H., Okamoto, H., Karato, A., Ohmatsu, H. (1992). Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J. Natl. Cancer Inst. 84:972-974.
36. Paoluzzi, L., Singh, A. S., Price, D. K., Danesi, R., Mathijssen, R. H., Verweij, J., Figg, W. D., Sparreboom, A. (2004). Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J. Clin. Pharmacol. 44:854-860.
37. Pharmaceuticals and Cosmetics Division, Pharmaceutical Affairs Bureau, Ministry of Health and Welfare (1996). Summary Basis of Approval (SBA) No.1 (Revised Edition): Irinotecan Hydrochloride. Tokyo: Yakuji Nippo, Ltd.
38. Pilot, H. C., Goldberg, R. M., Reid, J. M., Sloan, J. A., Skaff, P. A., Erlichman, C., Rubin, J., Burch, P. A., Adjei, A. A., Alberts, S. A., Schaaf, L. J., Elfring, G., Miller, L. L. (2000). Phases I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a onceevery-three-week dosing schedule for patients with advanced solid tumor malignancy. Clin. Cancer Res. 6:2236-2244.
39. Ritter, J. K., Chen, F., Sheen, Y. Y., Tran, H. M., Kimura, S., Yeatman, M. T., Owens, I. S. (1992). A novel complex locus UGTI encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini. J. Biol. Chem. 267:3257-3261.
40. Rivory, L. P., Haaz, M. C., Canal, P., Lokiec, F., Armand, J. P., Robert, J. (1997). Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. Clin. Cancer Res. 3:1261-1266.
41. Roses, A. D. (2000). Pharmacogenetics and the practice of medicine. Nature 405:857-865.
42. Rouits, E., Boisdron-Celle, M., Dumont, A., Guerin, O., Morel, A., Gamelin, E. (2004). Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin. Cancer Res. 10:5151-5159.
43. Sai, K., Saeki, M., Saito, Y., Ozawa, S., Katori, N., Jinno, H., Hasegawa, R., Kaniwa, N., Sawada, J., Komamura, K., Ueno, K., Kamakura, S., Kitakaze, M., Kitamura, Y., Kamatani, N., Minami, H., Ohtsu, A., Shirao, K., Yoshida, T., Saijo, N. (2004). UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecanadministered Japanese patients with cancer. Clin. Pharmacol. Ther. 75:501-515.
44. Senafi, S. B., Clarke, D. J., Burchell, B. (1994). Investigation of the substrate specificity of a cloned expressed human bilirubin UDP- glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation. Biochem. J. 303:233-240.
45. Sugatani, J., Yamakawa, K., Yoshinari, K., Machida, T., Takagi, H., Mori, M., Kakizaki, S., Sueyoshi, T., Negishi, M., Miwa, M. (2002). Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia. Biochem. Biophys. Res. Commun. 292:492-497.
46. Tadokoro, J., Hasegawa, H., Hayakawa, K., Takahashi, M., Nakata, H., Terada, K., Sakata, Y., Fukuoka, M. (2002). Post-marketing surveillance (PMS) of all patients treated with irinotecan in Japan: clinical experience and ADR profile of 13,935 patients. Proc. Am. Soc. Clin. Oncol. 21:259. (suppl.; abstr. 1033).
47. Wasserman, E., Myara, A., Lokiec, F., Goldwasser, F., Trivin, F., Mahjoubi, M., Misset, J. L., Cvitkovic, E. (1997). Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann. Oncol. 8:1049-1051.
48. Xie, R., Mathijssen, R. H. J., Sparreboom, A., Verweij, J., Karlsson, M. O. (2002). Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin. Pharmacol. Ther. 72:265-275.